Solana Company Stock Price, News & Analysis

Helius Medical Technologies (NASDAQ: HSDT) has secured claim authorization from CignaHealth for its Portable Neuromodulation Stimulator (PoNS) Device at an out-of-network adjusted negotiated price of $19,161. This marks CignaHealth as the fifth major payer to authorize claims for the PoNS Device, following a recent similar authorization from Anthem MultiPlan at $19,160. The PoNS Device is designed to treat balance and gait deficits in MS patients. CEO Dane Andreeff highlighted that these approvals demonstrate significant progress in increasing patient access and reinforce the device's value proposition. The company aims to achieve broader reimbursement from CMS and expanded healthcare coverage, though actual device sales may vary depending on individual patient deductibles and out-of-pocket costs.

Helius Medical Technologies (NASDAQ: HSDT) presented positive results from their PoNS Therapeutic Experience Program (PoNSTEP) study at the 2025 CMSC Annual Meeting. The study demonstrated lasting beneficial effects of PoNS Therapy on gait deficit improvement in Multiple Sclerosis patients. Dr. Deborah Backus highlighted that treatment adherence over 14 weeks led to clinically meaningful gait disability improvements, with effects sustained for 6 months post-treatment. The results align with previous evidence in traumatic brain injury patients. The company reported progress in obtaining reimbursement from federal and private payers, including the VA and out-of-network commercial payers, which is expected to improve therapy accessibility.

Helius Medical Technologies (NASDAQ: HSDT) has secured authorization for payment from Aetna Healthcare for its PoNS Device at an out-of-network negotiated price of $18,350. This makes Aetna the third major healthcare payer to provide PoNS reimbursement, joining Anthem and United. The PoNS Device, designed for balance and gait deficits, is currently reimbursed by VA/DoD at $26,228. CEO Dane Andreeff emphasized that out-of-network reimbursement is just the first step, as the company actively pursues broader in-network coverage at list price and continues negotiating case-by-case reimbursements. The company is also working towards securing Medicare coverage for MS patients. The negotiated out-of-network price represents a 30-40% reduction from typical in-network contracted payment rates.

Helius Medical Technologies (NASDAQ: HSDT) has announced pricing for a $9.1 million public offering, consisting of 2,768,600 shares of Class A common stock and accompanying warrants. The combined offering is priced at $3.27 per share and warrant. Each warrant will be exercisable for 2.5 years at an initial exercise price of $7.3575 per share, with adjustment provisions and a zero cash exercise option allowing exchange for 2.0 common shares. Maxim Group LLC is serving as the sole placement agent, with the offering expected to close on June 6, 2025. The company, which focuses on therapeutic neuromodulation for balance and gait deficits, will use the proceeds to support its business objectives.

Helius Medical Technologies (NASDAQ:HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has successfully met Nasdaq's minimum bid price requirement (Rule 5550(a)(2)). The company received formal confirmation from the Nasdaq Hearings Panel on June 3, 2025. However, Helius still needs to comply with the Equity Rule (Rule 5550(b)(1)) by June 30, 2025, as per the previously granted extension. The Nasdaq Listing Qualifications hearing process will remain active until Helius demonstrates full compliance with all continued listing requirements.

Helius Medical Technologies (NASDAQ: HSDT) will present final results of the PoNSTEP study at the 2025 CMSC Annual Meeting, demonstrating the effectiveness of their PoNS® device for MS patients with gait deficits. The study showed that higher adherence to PoNS Therapy led to better outcomes, with the most adherent patients achieving over 6 points improvement in Dynamic Gait Index (DGI) scores during the first 14 weeks. Notably, 95% of participants maintained their improvements at 6-month follow-up. The study included three phases: 2 weeks of supervised clinic therapy, 12 weeks of combined clinic and home use, and a 6-month follow-up. Patients with high adherence (85% of recommended 100-120 minutes daily) showed superior results compared to moderate adherence (70%). The device is currently covered by VA, DoD, and some commercial insurers.

Helius Medical Technologies (NASDAQ: HSDT) has secured reimbursement approval from United Healthcare for its Portable Neuromodulation Stimulator (PoNS®) Device, making it the second major healthcare provider after Anthem to offer coverage. The approved reimbursement amount totals $18,100, which includes patient co-payment and represents the adjusted list price for out-of-network status.

The PoNS Device is designed to improve balance and gait deficits while reducing fall risk. This development marks a significant milestone in Helius's strategy to expand patient access through commercial payor coverage and third-party reimbursement, particularly benefiting MS patients.

Helius Medical Technologies has announced a 1-for-15 reverse stock split of its Class A common stock, effective May 1, 2025. The split was approved by stockholders on April 21, 2025, allowing a ratio range of 1-for-2 to 1-for-30 to maintain Nasdaq listing compliance.

Starting May 2, 2025, the company's stock will trade on a split-adjusted basis under the same symbol "HSDT" on the Nasdaq Capital Market. The reverse split will reduce outstanding shares from approximately 7.9 million to 0.5 million, while maintaining the authorized share count at 150 million.

Key changes include:

• Every 15 shares will convert to one share
• $0.001 par value remains unchanged
• Fractional shares will be rounded down with cash compensation
• New CUSIP number: 42328V 884
• Proportional adjustments to stock options and warrants

Helius Medical Technologies (NASDAQ:HSDT) has announced the establishment of Revelation Neuro, a wholly-owned private subsidiary focused on developing non-implantable AI-powered Brain Computer Interface (BCI) technology. The subsidiary will leverage Helius' existing IP portfolio and extensive data warehouse for AI algorithm development.

The new venture aims to create a personalized neurorehabilitation solution using translingual stimulation without implantation. Revelation Neuro will utilize Helius' dataset of over 5 years of movement dysfunction clinical evidence from 400+ subjects as the foundation for AI algorithm development. The technology focuses initially on motor function rehabilitation, with potential future applications in cognitive deficit, mood, and behavior disorders.

While Helius will assign its newly developed IP and license existing IP to Revelation Neuro, the company does not plan to invest significant additional capital. Instead, the subsidiary is expected to be financed through third-party outside sources, building upon the $70 million already invested in neuromodulation technology development.